Quick Answer
CNS Pharmaceuticals, Inc. reported Operating Income Loss of -$15.99 million for the year ending 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -7.3% in Operating Income Loss from 2024 to 2025.
- This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$169.9 thousand | Q1 2019: -$195.1 thousand | Q2 2019: -$415.1 thousand | Q3 2019: -$699.1 thousand | Q1 2020: -$1.97 million | Q2 2020: -$2.47 million | Q3 2020: -$2.01 million | Q1 2021: -$3.61 million | Q2 2021: -$3.81 million | Q3 2021: -$3.81 million | Q1 2022: -$3.15 million | Q2 2022: -$3.56 million | Q3 2022: -$3.42 million | Q1 2023: -$4.93 million | Q2 2023: -$4.03 million | Q3 2023: -$4.53 million | Q1 2024: -$3.54 million | Q2 2024: -$2.53 million | Q3 2024: -$5.63 million | Q1 2025: -$4.34 million | Q2 2025: -$2.41 million | Q3 2025: -$3.25 million.
- Over the full 8 years of available data (2018 to 2025), CNS Pharmaceuticals, Inc.'s Operating Income Loss has declined by 1,713.0%.
- Historical annual values: Fiscal year 2025: -$15.99 million | Fiscal year 2024: -$14.90 million | Fiscal year 2023: -$18.87 million | Fiscal year 2022: -$15.27 million | Fiscal year 2021: -$14.49 million | Fiscal year 2020: -$9.45 million | Fiscal year 2019: -$3.83 million | Fiscal year 2018: -$881.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: